Bioavailability of a Novel, Water-Soluble Vitamin E Formulation in Malabsorbing Patients
- 10 January 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Digestive Diseases and Sciences
- Vol. 52 (2), 347-352
- https://doi.org/10.1007/s10620-006-9489-2
Abstract
In cystic fibrosis (CF), pancreatic insufficiency and a diminished bile acid pool cause malabsorption of important nutrients and dietary components leading to deficiency, poor nutritional status, and oxidative stress. Of particular significance is the malabsorption of fat-soluble nutrients and antioxidants, which are important for normal immune and neurologic function. Patients with CF often are deficient in these compounds despite supplementation with the current standard of care therapy. The objective was to compare the pharmacokinetic profile of this water-soluble vitamin E formulation (Aqua-E) with an oil-based softgel formulation in a malabsorbing patient population. Patients with CF who had documented malabsorption were recruited for participation in this pharmacokinetic study. Patients who met inclusion and exclusion criteria discontinued vitamin E supplementation, except for that in a multivitamin, for 7 to 21 days before the day of dosing. Patients were randomized to a single dose of 20 ml of Aqua-E or three oil-based softgels, which contained equivalent amounts of tocopherols. Blood was drawn from patients at time 0, 2, 4, 8, 24, 48, and 168 hr and analyzed for tocopherols. Eight patients were enrolled in the study and randomized to Aqua-E or softgels. The primary outcome, the absorption of γ-tocopherol in Aqua-E (AUC=115 μg/ml*hr), was significantly greater than that of oil-based softgels (AUC=25.3 μg/ml*hr; P=0.013). Total-tocopherols (α+γ+δ) in Aqua-E (AUC=294 μg/ml*hr) showed a strong trend toward increased absorption compared with that of oil-based softgels (AUC=117 μg/ml*hr; P=0.09). In conclusion, this novel, water-soluble formulation showed a marked and statistically significant increase in absorption of γ-tocopherol in malabsorbing patients with CF compared with an oil-based formulation.Keywords
This publication has 40 references indexed in Scilit:
- Tumor suppressive effects of tocotrienol in vivo and in vitroCancer Letters, 2005
- Tocotrienols reduce 25-hydroxycholesterol-induced monocyte–endothelial cell interaction by inhibiting the surface expression of adhesion moleculesAtherosclerosis, 2005
- Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal diseaseKidney International, 2003
- Water‐miscible tocopherol is not superior to fat‐soluble preparation for vitamin E absorption in cystic fibrosisActa Paediatrica, 2001
- Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosisThorax, 2001
- The Role of Nitric Oxide in NeurodegenerationDrugs & Aging, 1998
- Pulmonary dysfunction in cystic fibrosis is associated with oxidative stressEuropean Respiratory Journal, 1996
- Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: Improvement during vitamin E supplementationFree Radical Biology & Medicine, 1995
- Intestinal bile acid malabsorption in cystic fibrosis.Gut, 1993
- Carotenoid levels in normal children and in children with cystic fibrosisThe Journal of Pediatrics, 1993